Methylene blue, a synthetic dye first created in the 1870s and used for decades to treat conditions like methemoglobinemia and urinary tract infections, has attracted growing attention from cancer researchers for its ability to kill tumor cells through multiple distinct pathways. Preclinical studies show it can shrink tumors when activated by light, poison cancer cells even in the dark, and sensitize resistant tumors to chemotherapy drugs. Most of this evidence comes from cell cultures and animal models, with only a handful of human clinical trials completed so far, but the breadth of activity across different cancer types has made it one of the more intriguing drug-repurposing candidates in oncology.
Why Cancer Cells Absorb More Methylene Blue
One reason researchers keep returning to methylene blue is that cancer cells appear to soak up more of it than healthy cells do. The dye carries a positive charge and is drawn into mitochondria, the energy-producing compartments inside cells. Cancer cells tend to have a higher voltage difference across their mitochondrial membranes compared to normal cells. In breast cancer cells, for example, this membrane potential runs at least 60 millivolts higher than in normal breast tissue, which drives substantially greater accumulation of the dye inside the cancer cell’s mitochondria and lysosomes.1Scientific Reports. Fluorescence Polarization of Methylene Blue as a Quantitative Marker of Breast Cancer at the Cellular Level That built-in selectivity matters because it means a dose of methylene blue that concentrates inside a tumor may spare surrounding healthy tissue to some degree. Lab comparisons back this up: when tested against erythroleukemic cells and melanoma cells alongside their normal counterparts (lymphocytes and melanocytes), methylene blue was more toxic to the cancer lines.2PubMed. Methylene blue is more toxic to erythroleukemic cells than to normal peripheral blood mononuclear cells: a possible use in chemotherapy
Photodynamic Therapy and How It Works
The most heavily studied anticancer use of methylene blue involves photodynamic therapy, or PDT. The idea is straightforward: inject the dye, wait for it to concentrate in tumor tissue, then shine a specific wavelength of light on the area. When light hits the dye molecules, they transfer energy to nearby oxygen, generating reactive oxygen species that tear apart cell membranes, damage DNA, and trigger programmed cell death. Methylene blue absorbs light strongly in the red and near-infrared range, which gives it an advantage because longer-wavelength light penetrates tissue more deeply than shorter wavelengths.3Photodiagnosis and Photodynamic Therapy. Methylene blue in photodynamic therapy: From basic mechanisms to clinical applications
In melanoma cells specifically, researchers traced the chain of events after light activation: the burst of reactive oxygen species trips an internal alarm system called the caspase-9/caspase-3 pathway, which pushes the cell into apoptosis, a controlled form of self-destruction.4PubMed Central. Apoptosis induced by methylene‐blue‐mediated photodynamic therapy in melanomas and the involvement of mitochondrial dysfunction revealed by proteomics A systematic review of preclinical PDT studies found tumor shrinkage ranging from about 12% to complete elimination across seven animal studies, with the treatment showing activity against colorectal tumors, carcinoma, and melanoma. Even in cases where tumors did not shrink, the treated animals showed slower tumor growth compared to controls.5Frontiers in Pharmacology. Methylene blue in anticancer photodynamic therapy: systematic review of preclinical studies
Skin cancers are a natural fit for PDT because the tumor sits at the surface where light can reach it easily. For squamous cell carcinoma, researchers have been testing methylene blue loaded into nanoparticles to improve how much of the dye penetrates the skin and reaches the tumor. When nanoparticle-encapsulated methylene blue was activated by light, it killed skin cancer cells at concentrations roughly four times lower than free methylene blue solution required.6PubMed Central. Nanoencapsulation of Methylene-Blue for Enhanced Skin Cancer Cell Phototoxicity and Cutaneous Penetration in Association with Sonophoresis
Killing Cancer Cells Without Light
Methylene blue does not need to be activated by light to harm cancer cells, a property researchers call “dark cytotoxicity.” Early experiments on human neuroblastoma and astrocytoma cells showed that the dye killed brain tumor cells in a dose-dependent manner without any light exposure at all.7PubMed. Methylene blue induces cytotoxicity in human brain tumor cells The mechanism here is different from PDT. Instead of generating reactive oxygen species through light, methylene blue interferes with cancer cell metabolism directly.
One of the most interesting metabolic angles involves what is sometimes called the Warburg effect, the tendency of cancer cells to rely on inefficient sugar fermentation for energy rather than the normal oxygen-dependent process, even when oxygen is available. In glioblastoma cell lines, methylene blue reversed this metabolic shift: treated cells consumed more oxygen and produced less lactate, essentially forcing them back toward normal energy metabolism.8PubMed Central. Reversing the Warburg effect as a treatment for glioblastoma This matters because the Warburg effect is thought to give cancer cells a survival advantage, and stripping it away could make them more vulnerable.
The underlying chemistry that lets methylene blue tinker with cell energy involves its ability to shuttle electrons inside mitochondria. It can accept electrons from one part of the energy-production chain and hand them off further down the line, essentially providing an alternate wiring path for the cell’s power system.9PubMed Central. Alternative mitochondrial electron transfer for the treatment of neurodegenerative diseases and cancers: Methylene blue connects the dots In healthy cells, this bypass can be protective. In cancer cells with already-disrupted mitochondria, it appears to push them past a tipping point.
An ovarian cancer study demonstrated how pronounced this effect can be: treating TOV112D ovarian cancer cells with methylene blue knocked their proliferation down to roughly 16% of untreated controls, while normal retinal cells under the same conditions retained about 53% of their growth rate.10PubMed Central. Methylene Blue Metabolic Therapy Restrains In Vivo Ovarian Tumor Growth That gap between cancer-cell sensitivity and normal-cell tolerance is exactly the kind of therapeutic window drug developers look for.
Making Chemotherapy and Other Treatments Work Better
Some of the more practical near-term potential for methylene blue may lie not in using it as a standalone drug, but in combining it with existing cancer treatments. In metastatic melanoma cells, methylene blue suppressed the heat shock response, a defense mechanism cancer cells use to survive the stress of chemotherapy drugs. When melanoma cells were co-treated with methylene blue alongside drugs like etoposide and doxorubicin, the cancer cells became significantly more sensitive to those chemotherapies.11PubMed Central. Phenotypic identification of the redox dye methylene blue as an antagonist of heat shock response gene expression in metastatic melanoma cells
Drug resistance is one of the most stubborn problems in oncology. Many cancers develop the ability to pump drugs back out of the cell before they can do damage, a phenomenon known as multidrug resistance. Methylene blue has been shown to reverse this pumping mechanism, and when tested across five cell lines with and without the resistance trait, sensitivity to its light-activated killing was the same regardless of whether the cells were drug-resistant.12Surgical Oncology. Methylene blue reverts multidrug resistance: sensitivity of multidrug resistant cells to this dye and its photodynamic action That dual role as both a resistance reverser and a direct cancer-killing agent is unusual and potentially valuable.
Combining methylene blue PDT with the chemotherapy drug doxorubicin against colorectal cancer cells produced greater cell death than either treatment alone, with higher levels of membrane damage and oxidative stress in the combination group.13PubMed Central. Methylene Blue-Mediated Photodynamic Therapy in Combination With Doxorubicin: A Novel Approach in the Treatment of HT-29 Colon Cancer Cells
Waking Up the Immune System
A newer and particularly exciting line of research involves immunogenic cell death. When cancer cells die in certain ways, they spill molecular signals that alert the immune system to the presence of the tumor. Methylene blue PDT in lung cancer cells triggered this kind of immunologically visible death: treated cells displayed distress signals on their surface, including calreticulin and MHC-I molecules, which essentially flag the dying cell for immune recognition. The treatment also boosted the ability of CD8+ T cells to kill lung cancer cells through granzyme B, a mechanism tested in both standard cell cultures and three-dimensional human lung cancer organoids that more closely mimic real tumor architecture.14PubMed Central. Phototherapeutic Induction of Immunogenic Cell Death and CD8+ T Cell-Granzyme B Mediated Cytolysis in Human Lung Cancer Cells and Organoids
If this finding holds up in animal models and eventually in humans, it could mean that methylene blue PDT does not just kill the cells it directly contacts but trains the patient’s immune system to hunt remaining cancer cells. That kind of abscopal effect, where treating one tumor site leads to immune responses against distant tumors, is the holy grail of cancer immunotherapy research. The evidence here is still early-stage, but it adds another dimension to why the compound keeps attracting attention.
Nanoparticle Delivery Systems
Plain methylene blue dissolved in solution has real limitations. It gets broken down quickly in the body, it can leach out of tumor tissue, and in the case of brain tumors, the concentrations needed inside the tumor risk damaging healthy tissue along the way. Much of the recent research has focused on packaging methylene blue inside nanoparticles to improve how long it circulates, how much reaches the tumor, and how precisely it can be delivered.
Polydopamine-coated liposomes loaded with methylene blue showed stronger cancer-killing power than free methylene blue in both flat cell cultures and three-dimensional tumor spheroids, likely because the nanoparticles improved cellular uptake and reactive oxygen species production during light activation.15PubMed Central. Polydopamine-Coated Liposomes for Methylene Blue Delivery in Anticancer Photodynamic Therapy: Effects in 2D and 3D Cellular Models Another approach used an active loading method with an ammonium sulfate gradient to pack more dye into liposomes, achieving encapsulation of about 84% compared to roughly 38% for passive loading. Adding a targeting molecule aimed at the epidermal growth factor receptor, which is overexpressed on many cancer cell surfaces, dropped the concentration needed to kill half the cells to about 0.38 micromolar, roughly five times lower than untargeted liposomes required.16Journal of Pharmaceutical Sciences. Development of an active loading strategy for methylene blue in liposomes and its application in EGFR-targeted photodynamic therapy
For brain tumors, the challenge is getting anything past the blood-brain barrier. Methylene blue can cross this barrier on its own, but at the therapeutic concentrations needed against glioblastoma, free dye causes collateral damage to healthy brain tissue. Nanoparticle-encapsulated versions crossed the barrier more effectively than free dye in mouse studies, raising the possibility of delivering enough drug to the tumor while keeping concentrations lower elsewhere.17PubMed Central. Development and Characterization of Methylene Blue Oleate Salt-Loaded Polymeric Nanoparticles and their Potential Application as a Treatment for Glioblastoma Hydrogel nanoparticles conjugated with tumor-targeting peptides have also been shown to specifically home in on selected tumor cell lines while minimizing dye leaching.18Macromolecular Bioscience. Methylene Blue-Conjugated Hydrogel Nanoparticles and Tumor-Cell Targeted Photodynamic Therapy
Surgical Guidance and Tumor Imaging
While killing cancer cells gets the most attention, methylene blue is already finding use in the operating room as a tool for seeing tumors more clearly. The dye fluoresces in the near-infrared range, and because cancer tissue absorbs more of it than surrounding healthy tissue, surgeons can use specialized cameras to visualize tumor margins in real time. In a preliminary study of breast cancer surgery, patients received an intravenous injection of methylene blue three hours before their operation. The resected tissue was then imaged with a near-infrared fluorescence system, and the dye successfully highlighted tumor boundaries, pointing toward a future role in helping surgeons remove as much cancer as possible while sparing healthy breast tissue during conserving procedures.19PubMed Central. Methylene Blue–Based Near-Infrared Fluorescence Imaging for Breast Cancer Visualization in Resected Human Tissues
Gastric cancer presents a different scenario. Researchers found that methylene blue is taken up specifically by gastric epithelial cells, meaning it highlights the stomach lining rather than targeting stomach tumors directly. While that might sound like a limitation, it actually creates a useful negative-imaging technique: the normal stomach lining glows, and the tumor, which does not absorb the dye as well, shows up as a dark spot. This contrast could help surgeons identify precise resection margins during stomach cancer operations.20Frontiers in Bioengineering and Biotechnology. Near-infrared fluorophores methylene blue for targeted imaging of the stomach in intraoperative navigation
In colorectal cancer, the role is more established. A meta-analysis of eighteen clinical trials found that injecting methylene blue into the blood supply of colorectal specimens helped pathologists harvest significantly more lymph nodes than standard dissection, including more cases reaching the minimum threshold of twelve nodes needed for adequate cancer staging.21Surgical Oncology. The impact of methylene blue in colorectal cancer: Systematic review and meta-analysis study Better lymph node counts mean more accurate staging, which directly affects treatment decisions.
How Methylene Blue Behaves Inside the Body
After intravenous injection, methylene blue distributes rapidly. In tumor tissue specifically, the dye transitions within minutes to leucomethylene blue, its colorless reduced form, with peak accumulation in the tumor occurring about five to ten minutes after injection at doses of 10 to 20 mg/kg in animal studies.22Photodiagnosis and Photodynamic Therapy. The use of methylene blue to control the tumor oxygenation level This rapid conversion is relevant because the reduced form and the oxidized form have different biological activities. The interplay between the two states inside a tumor likely influences both the dye’s therapeutic effect and how much reactive oxygen species it generates during PDT. For surgical imaging, the timing matters too: if the dye converts too quickly, the fluorescence window narrows.
What Human Trials Have Actually Shown
The honest reality is that clinical data for methylene blue as a cancer treatment remains thin. The vast majority of the evidence described above comes from cell cultures and animal models, and the history of oncology is littered with compounds that looked promising in the lab and failed in people. Still, a few human studies have been completed.
A randomized phase 2 trial tested methylene blue oral rinse for the severe mouth pain caused by oral mucositis, a devastating side effect of cancer treatment that makes it hard to eat, drink, or speak. Patients who used methylene blue rinses at various concentrations experienced significantly lower pain scores by day two compared to those receiving standard treatment alone. No serious adverse events occurred, though a small number of patients reported a burning sensation with the first dose.23PubMed Central. Methylene blue for intractable pain from oral mucositis related to cancer treatment: a randomized phase 2 clinical trial This trial addressed cancer-treatment side effects rather than tumors themselves, but it represents one of the more rigorous clinical datasets available.
The colorectal lymph node meta-analysis mentioned earlier is probably the strongest body of clinical evidence, drawing on eighteen trials. But its clinical value is in improving diagnosis and staging rather than directly treating the cancer.
Safety Concerns and Drug Interactions
Methylene blue has a long safety record at the low doses used for its FDA-approved indications, but cancer treatment would likely require different dosing strategies and routes of administration, and the safety profile at those levels is less well characterized. The most clinically dangerous known interaction involves serotonin. Methylene blue is a potent inhibitor of the enzyme monoamine oxidase A, which breaks down serotonin. At concentrations reached after intravenous administration, this enzyme would be almost completely blocked.24PubMed Central. Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction For anyone taking an SSRI antidepressant or other serotonergic medication, adding methylene blue can trigger serotonin toxicity, a potentially life-threatening condition involving agitation, fever, muscle rigidity, and seizures. Even small doses previously considered safe have precipitated this reaction in patients on SSRIs.25PubMed. Small doses of methylene blue, previously considered safe, can precipitate serotonin toxicity
Other known effects at higher doses include a temporary bluish discoloration of skin and urine, which is harmless but sometimes alarming for patients who are not warned. In people with a genetic deficiency of the enzyme glucose-6-phosphate dehydrogenase (G6PD), methylene blue can cause hemolytic anemia rather than treating methemoglobinemia as it normally does. Any future cancer application would need to screen patients for G6PD status and serotonergic drug use before administration.
Where Nanoparticle Research Is Heading
The variety of nanoparticle platforms being tested with methylene blue reflects how active this area is and how far it remains from clinical readiness. Liposomes, hydrogel particles, polydopamine coatings, and polymer nanoparticles have all been tried, each addressing slightly different delivery problems. The targeting approach using EGFR-binding molecules is particularly relevant because EGFR overexpression appears across many cancer types, including head and neck, lung, and colorectal cancers. If a single nanoparticle formulation could deliver methylene blue selectively to EGFR-positive tumors, activate it with light, and simultaneously release a chemotherapy drug, that would represent a genuine advance over current PDT approaches. Several groups are working on exactly that kind of multi-functional particle, but none has progressed to human trials for anticancer PDT yet.
The gap between bench and bedside here is not just about proving that the nanoparticles work. Regulatory agencies require extensive toxicology data for nanoparticle formulations, and manufacturing them reproducibly at scale is a persistent engineering challenge. Methylene blue itself is cheap and off-patent, which is both an advantage (low production cost, well-known pharmacology) and a disadvantage (less commercial incentive for a pharmaceutical company to invest in expensive clinical trials). The most likely path forward involves academic medical centers running investigator-initiated trials, probably for cancers where PDT is already accepted as a treatment modality, like certain skin cancers and esophageal tumors where light can be delivered easily via fiber optics.